First Trust Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

First Trust Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-208	Closed	-$4.07M	–	234
2022 Q4	$4.07M	Hold	208	–	–	0.22%	143
2022 Q3	$3.94M	Buy	+208	New	+$3.99M	0.19%	165

Other funds holding CLDI

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

Bank of Montreal

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Elequin Capital New York $3.36B AUM 11.23% 1-Year Est. Return

First Trust Capital Management's CLDI Position: Q1 2023 in Review

First Trust Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q1 2023, closing a stake of 208 shares — an estimated $4.07M sold.

First Trust Capital Management first reported a position in CLDI in Q3 2022 and held it in 2 quarters. The position peaked at $4.07M in Q4 2022. 26 funds tracked by Wall St. Rank hold CLDI as of Q1 2023.

First Trust Capital Management reported no remaining Calidi Biotherapeutics position as of Q1 2023 after selling out during the quarter.
First Trust Capital Management sold 208 Calidi Biotherapeutics shares in Q1 2023, an estimated $4.07M.
First Trust Capital Management first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 2 quarters.
First Trust Capital Management's Calidi Biotherapeutics position peaked at $4.07M in Q4 2022.
26 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2023.

Based on First Trust Capital Management's 13F filing for Q1 2023, filed 12 May 2023.